top of page
Leading the Way in Intratumoral Radiotherapeutics
News
Categories
Sign up
Featured Posts
Archive
Follow Us
Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial
- First patient treatment marks successful initiation of multi-center pilot study in Alpha DaRT U.S. pancreatic cancer program – - Study...
Sep 2
Alpha Tau to Participate in Five September Investor Conferences
JERUSALEM, August 27, 2025 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...
Aug 27
Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update
- FDA approval of IDE to conduct a U.S. pilot study exploring the use of Alpha DaRT in patients with recurrent glioblastoma multiforme...
Aug 12
Combining Alpha DaRT® and Immunotherapy: Early Results and Clinical PromiseAn interview with Prof. Aron Popovtzer
Combining Alpha DaRT® and Immunotherapy: Early Results and Clinical Promise An interview with Prof. Aron Popovtzer, Director of Sharett...
Jul 10
Alpha Tau to Present at Jefferies Global Healthcare Conference
JERUSALEM, May 28, 2025 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative...
May 28
bottom of page